-+ 0.00%
-+ 0.00%
-+ 0.00%

Barrington Research Maintains Outperform on Anika Therapeutics, Raises Price Target to $16

Benzinga·11/06/2025 20:19:59
Listen to the news
Barrington Research analyst Michael Petusky maintains Anika Therapeutics (NASDAQ:ANIK) with a Outperform and raises the price target from $15 to $16.